How should you price new therapies when the standard of care is not cost effective?

Let’s say that there is a very severe disease—let’s call it horriblitis—with significant impacts on patient morbidity and mortality.  The only available treatment for horriblitis is drug called BlackPill.  BlackPill improves health outcomes by 1 QALY over best supportive care (BSC), but costs $500,000 over the patient’s lifetime.   While not cost effective by traditional standards,…

Read More

Who is Speaking at INVEST 2025?

The healthcare investor conference, scheduled for May 20 and 21 at the Willis Tower in Chicago, combines panel discussions, networking opportunities, and a startup pitch contest. Register today! The post Who is Speaking at INVEST 2025? appeared first on MedCity News.

Read More